Wait-and-scan strategy feasible for head, neck paraganglioma

July 17, 2017

(HealthDay)—A wait-and-scan strategy seems to be feasible for patients with head and neck paraganglioma (PGL), according to a study published online July 10 in Head & Neck.

Thijs T.G. Jansen, from the Radboud University Medical Center in Nijmegen, Netherlands, and colleagues conducted a involving patients with head and neck PGL. The authors measured tumor growth in axial plane diameter and volume during a wait-and-scan period.

The researchers found that 44 percent of 59 jugulotympanic tumors, 71 carotid body tumors, and 29 vagal body tumors were growing (median growth rates, 0.41, 1.6, and 1.6 mm/year, respectively). There was a significant correlation for growth with age at presentation (odds ratio, 0.974; P < 0.05). Twenty complications were induced by 17 tumors; six of these were growing, and the rates were higher than in non-complication-inducing tumors (P = 0.016).

"The results of this study illustrate that a wait-and-scan policy is a feasible treatment option in cases for head and PGL, as it potentially prevents treatment-induced morbidity in the majority of patients, including those presenting larger tumors," the authors write. "Our results also suggest that radiological follow-up is not an optimal management strategy, because a large group of tumors were found not to grow, although they did elicit complications, in the main, years after the initial diagnosis."

Explore further: Report describes primary clear cell sarcoma of head, neck

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Report describes primary clear cell sarcoma of head, neck

June 13, 2016
(HealthDay)—Three cases of primary clear cell sarcoma of the head and neck have been described in three male patients, according to a review published online June 6 in the Journal of Cutaneous Pathology.

Reduced cancer-independent life expectancy in head, neck cancer

June 27, 2017
(HealthDay)—Patients with head and neck cancer have reduced life expectancy, independent of cancer, according to a study published online June 22 in Head & Neck.

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer ...

Smoking, T4 tumors up distant mets in HPV+ oropharyngeal CA

February 15, 2017
(HealthDay)—For patients with human papillomavirus (HPV)-positive oropharyngeal cancer, active smokers and those with T4 tumors have increased rates of distant metastases, according to a study published online Feb. 11 in ...

More side effects with CRT plus metformin in head, neck cancer

May 7, 2017
(HealthDay)—Patients with advanced head and neck cancer undergoing chemoradiotherapy (CRT) and receiving metformin experience more side effects than patients not on metformin, according to research published online April ...

Recommended for you

'Kiss of death' cancer: How computational geeks may have uncovered a therapy for a deadly disease

June 19, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients ...

Team discovers gene mutations linked to pancreatic cancer

June 19, 2018
Six genes contain mutations that may be passed down in families, substantially increasing a person's risk for pancreatic cancer. That's according to Mayo Clinic research published in the June 19 edition of the JAMA. However, ...

Breast cancer could be prevented by targeting epigenetic proteins, study suggests

June 19, 2018
Researchers at the Princess Margaret Cancer Centre in Toronto have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study, which will ...

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.